Clinical trials

  • SARUPARIB for Metastatic prostate cancer
  • N-[4-({[(1R,4R)-4-HYDROXY-4-METHYLCYCLOHEXYL]METHYL}AMINO)-3- NITROBENZENE-1-SULFONYL]-4-(2-{(2S)-2-[2-(PROPAN-2-YL)PHENYL]PYRROLIDIN1-YL}-7-AZASPIRO[3.5]NONAN-7-YL)-2-[(1H-PYRROLO[2,3-B]PYRIDIN-5- YL)OXY]BENZAMIDE for Myeloid malignancies | Acute myeloid leukemia | Myelodysplastic syndromes | Myelodysplastic syndrome/myeloproliferative neoplasm
  • METFORMIN EMBONATE for Portal hypertension | Cirrhosis
  • FINERENONE for Heart failure | Acute heart failure
  • RAVULIZUMAB for Neuromyelitis optica spectrum disorder (AQP4-antibody positive)
  • ISATUXIMAB for Relapsed and/or refractory multiple myeloma | Recurrent plasma cell myeloma
  • Trametinib for Low-grade glioma | Mixed glio-neuronal tumour | Pleomorphic xanthoastrocytoma (PXA)
  • ALPRAZOLAM for Prolonged seizure|Stereotypical prolonged seizure
  • TECAGINLIMAB for Malignant solid tumour|Melanoma|Non-small cell lung cancer|Head and neck squamous cell carcinoma|Pancreatic ductal adenocarcinoma|Colorectal cancer
  • Durvalumab for Oropharyngeal squamous cell carcinoma | Locoregionally advanced HPV-positive oropharyngeal squamous cell carcinoma (intermediate risk)
  • ALPELISIB for PIK3CA-related overgrowth spectrum (PROS)
  • Ribociclib for Breast cancer (estrogen receptor-positive [ER+], HER2-negative) | Operable stage II breast cancer